Consensus statement on the use of biosimilar drugs in immune-mediated diseases in Spain

Objective: To improve knowledge about biosimilar medicines and to generate a consensus framework on their use.Methods: Qualitative study. A multidisciplinary group of experts in biosimilar medicines was established (1 dermatologist, 1 hospital pharmacist, 1 rheumatologist, and 1 gastroenterologist) who defined the sections and topics of the document. A narrative literature review was performed in Medline to identify on biosimilar medicines. Systematic reviews, controlled, pre-clinical, clinical, and real-life studies were selected. Based on the results of the review, several general principles and recommendations were generated. The level of agreement was tested in a Delphi that was extended to 66 health professionals who voted from 1 (totally disagree) to 10 (totally agree). Agreement was defined if at least 70% of the participants voted >= 7.Results: The literature review included 555 articles. A total of 10 general principles and recommendations were voted upon. All reached the level of agreement established. The document includes data on the main characteristics of biosimilar medicines (definition, development, approval, indication extrapolation, interchangeability, financing, and traceability); published evidence (biosimilarity, efficacy, effectiveness, safety, immunogenicity, efficiency, switch); barriers and facilitators to its use; and data on information for patients.Conclusions: Authorized biosimilar medicines meet all the characteristics of quality, efficacy, and safety. They also significantly help improve patient access to biological therapies and contribute to health system sustainability.(c) 2022 Elsevier Espana, S.L.U. and Sociedad Espanola de Reumatologia y Colegio Mexicano de Reumatologia. All rights reserved.

Automated summary

This study aims to improve knowledge and generate a consensus framework on the use of biosimilar medicines. Through qualitative research and literature review, the characteristics, evidence, barriers and facilitators of biosimilar medicines, as well as patient information, were examined. The findings indicate that authorized biosimilar medicines meet the requirements of quality, efficacy, and safety, and play a significant role in improving patient access to biological therapies and the sustainability of the healthcare system.